Cholesterol Disorders


The Practical Cardiology™ Cholesterol Disorders clinical resource center offers the latest information from the field of lipidology. With hypercholesterolemia and hyperlipidemia representing a crucial aspect of risk management, this page will be a hub for information related to the latest in cholesterol management and dyslipidemia, including articles, videos, and podcasts.

Inside Cardiology: Lipid Management in 2021

April 05, 2021

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Rosuvastatin/Ezetimibe Combination Therapy Approved for Lowering LDL-C

April 05, 2021

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Evinacumab (Evkeeza) Receives FDA Approval as Adjunct Therapy for HoFH

February 11, 2021

A statement from Regeneron announced their ANGPTL3 inhibitor evinacumab (Evkeeza) received approval as an adjunct therapy for lowering LDL-C in patients 12 years and older with homozygous familial hypercholesterolemia.